BACKGROUND: We examined the effect of the novel Alzheimer's disease (AD) risk variant rs11136000 single nucleotide polymorphism in the clusterin gene (CLU) on longitudinal changes in resting state regional cerebral blood flow (rCBF) during normal aging and investigated its influence on cognitive decline in presymptomatic stages of disease progression. METHODS: Subjects were participants in the Baltimore Longitudinal Study of Aging. A subset of 88 cognitively normal older individuals had longitudinal (15)O-water positron emission tomography measurements of rCBF at baseline and up to eight annual follow-up visits. We also analyzed trajectories of cognitive decline among CLU risk carriers and noncarriers in individuals who remained cognitively normal (n = 599), as well as in those who subsequently converted to mild cognitive impairment or AD (n = 95). RESULTS: Cognitively normal carriers of the CLU risk allele showed significant and dose-dependent longitudinal increases in resting state rCBF in brain regions intrinsic to memory processes. There were no differences in trajectories of memory performance between CLU risk carriers and noncarriers who remained cognitively normal. However, in cognitively normal individuals who eventually converted to mild cognitive impairment or AD, CLU risk carriers showed faster rates of decline in memory performance relative to noncarriers in the presymptomatic stages of disease progression. CONCLUSIONS: The AD risk variant CLU influences longitudinal changes in brain function in asymptomatic individuals and is associated with faster cognitive decline in presymptomatic stages of disease progression. These results suggest mechanisms underlying the role of CLU in AD and may be important in monitoring disease progression in at-risk elderly.
BACKGROUND: We examined the effect of the novel Alzheimer's disease (AD) risk variant rs11136000 single nucleotide polymorphism in the clusterin gene (CLU) on longitudinal changes in resting state regional cerebral blood flow (rCBF) during normal aging and investigated its influence on cognitive decline in presymptomatic stages of disease progression. METHODS: Subjects were participants in the Baltimore Longitudinal Study of Aging. A subset of 88 cognitively normal older individuals had longitudinal (15)O-water positron emission tomography measurements of rCBF at baseline and up to eight annual follow-up visits. We also analyzed trajectories of cognitive decline among CLU risk carriers and noncarriers in individuals who remained cognitively normal (n = 599), as well as in those who subsequently converted to mild cognitive impairment or AD (n = 95). RESULTS: Cognitively normal carriers of the CLU risk allele showed significant and dose-dependent longitudinal increases in resting state rCBF in brain regions intrinsic to memory processes. There were no differences in trajectories of memory performance between CLU risk carriers and noncarriers who remained cognitively normal. However, in cognitively normal individuals who eventually converted to mild cognitive impairment or AD, CLU risk carriers showed faster rates of decline in memory performance relative to noncarriers in the presymptomatic stages of disease progression. CONCLUSIONS: The AD risk variant CLU influences longitudinal changes in brain function in asymptomatic individuals and is associated with faster cognitive decline in presymptomatic stages of disease progression. These results suggest mechanisms underlying the role of CLU in AD and may be important in monitoring disease progression in at-risk elderly.
Authors: Jason J Corneveaux; Amanda J Myers; April N Allen; Jeremy J Pruzin; Manuel Ramirez; Anzhelika Engel; Michael A Nalls; Kewei Chen; Wendy Lee; Kendria Chewning; Stephen E Villa; Hunsar B Meechoovet; Jill D Gerber; Danielle Frost; Hollie L Benson; Sean O'Reilly; Lori B Chibnik; Joshua M Shulman; Andrew B Singleton; David W Craig; Kendall R Van Keuren-Jensen; Travis Dunckley; David A Bennett; Philip L De Jager; Christopher Heward; John Hardy; Eric M Reiman; Matthew J Huentelman Journal: Hum Mol Genet Date: 2010-06-09 Impact factor: 6.150
Authors: S M Resnick; A F Goldszal; C Davatzikos; S Golski; M A Kraut; E J Metter; R N Bryan; A B Zonderman Journal: Cereb Cortex Date: 2000-05 Impact factor: 5.357
Authors: G W Small; L M Ercoli; D H Silverman; S C Huang; S Komo; S Y Bookheimer; H Lavretsky; K Miller; P Siddarth; N L Rasgon; J C Mazziotta; S Saxena; H M Wu; M S Mega; J L Cummings; A M Saunders; M A Pericak-Vance; A D Roses; J R Barrio; M E Phelps Journal: Proc Natl Acad Sci U S A Date: 2000-05-23 Impact factor: 11.205
Authors: Ronald B DeMattos; Mark A O'dell; Maia Parsadanian; Jennie W Taylor; Judith A K Harmony; Kelly R Bales; Steven M Paul; Bruce J Aronow; David M Holtzman Journal: Proc Natl Acad Sci U S A Date: 2002-07-26 Impact factor: 11.205
Authors: Ronald B DeMattos; John R Cirrito; Maia Parsadanian; Patrick C May; Mark A O'Dell; Jennie W Taylor; Judith A K Harmony; Bruce J Aronow; Kelly R Bales; Steven M Paul; David M Holtzman Journal: Neuron Date: 2004-01-22 Impact factor: 17.173
Authors: Antonio Terracciano; Lenuta Balaci; Jason Thayer; Matthew Scally; Sarah Kokinos; Luigi Ferrucci; Toshiko Tanaka; Alan B Zonderman; Serena Sanna; Nazario Olla; Maria Antonietta Zuncheddu; Silvia Naitza; Fabio Busonero; Manuela Uda; David Schlessinger; Gonçalo R Abecasis; Paul T Costa Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2009-12-05 Impact factor: 3.568
Authors: Sudha Seshadri; Annette L Fitzpatrick; M Arfan Ikram; Anita L DeStefano; Vilmundur Gudnason; Merce Boada; Joshua C Bis; Albert V Smith; Minerva M Carassquillo; Jean Charles Lambert; Denise Harold; Elisabeth M C Schrijvers; Reposo Ramirez-Lorca; Stephanie Debette; W T Longstreth; A Cecile J W Janssens; V Shane Pankratz; Jean François Dartigues; Paul Hollingworth; Thor Aspelund; Isabel Hernandez; Alexa Beiser; Lewis H Kuller; Peter J Koudstaal; Dennis W Dickson; Christophe Tzourio; Richard Abraham; Carmen Antunez; Yangchun Du; Jerome I Rotter; Yurii S Aulchenko; Tamara B Harris; Ronald C Petersen; Claudine Berr; Michael J Owen; Jesus Lopez-Arrieta; Badri N Varadarajan; James T Becker; Fernando Rivadeneira; Michael A Nalls; Neill R Graff-Radford; Dominique Campion; Sanford Auerbach; Kenneth Rice; Albert Hofman; Palmi V Jonsson; Helena Schmidt; Mark Lathrop; Thomas H Mosley; Rhoda Au; Bruce M Psaty; Andre G Uitterlinden; Lindsay A Farrer; Thomas Lumley; Agustin Ruiz; Julie Williams; Philippe Amouyel; Steve G Younkin; Philip A Wolf; Lenore J Launer; Oscar L Lopez; Cornelia M van Duijn; Monique M B Breteler Journal: JAMA Date: 2010-05-12 Impact factor: 56.272
Authors: Jessica R Marden; Elizabeth R Mayeda; Stefan Walter; Alexandre Vivot; Eric J Tchetgen Tchetgen; Ichiro Kawachi; M Maria Glymour Journal: Alzheimer Dis Assoc Disord Date: 2016 Jul-Sep Impact factor: 2.703
Authors: Adam E Green; Jeremy R Gray; Colin G Deyoung; Timothy R Mhyre; Robert Padilla; Amanda M Dibattista; G William Rebeck Journal: Neuropsychologia Date: 2014-01-02 Impact factor: 3.139
Authors: Minerva M Carrasquillo; Julia E Crook; Otto Pedraza; Colleen S Thomas; V Shane Pankratz; Mariet Allen; Thuy Nguyen; Kimberly G Malphrus; Li Ma; Gina D Bisceglio; Rosebud O Roberts; John A Lucas; Glenn E Smith; Robert J Ivnik; Mary M Machulda; Neill R Graff-Radford; Ronald C Petersen; Steven G Younkin; Nilüfer Ertekin-Taner Journal: Neurobiol Aging Date: 2014-08-04 Impact factor: 4.673
Authors: P Kochunov; J Charlesworth; A Winkler; L E Hong; T E Nichols; J E Curran; E Sprooten; N Jahanshad; P M Thompson; M P Johnson; J W Kent; B A Landman; B Mitchell; S A Cole; T D Dyer; E K Moses; H H H Goring; L Almasy; R Duggirala; R L Olvera; D C Glahn; J Blangero Journal: Neuroimage Date: 2013-05-24 Impact factor: 6.556